SequelSEC

ORAGENICS INC OGEN

Pharmaceutical Preparations · CIK 0001174940 · Fiscal year ends 1231

Revenue
$37.65K
Fiscal year ended 2023-12-31
Operating income
-$20.90M
Fiscal year ended 2023-12-31
Free cash flow
Unavailable
Fiscal year ended 2023-12-31

ORAGENICS INC (OGEN) reported revenue of $37.65K and net income of -$20.66M for the fiscal year ended 2023-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from ORAGENICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ORAGENICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312017-12-312016-12-312015-12-312014-12-31
Revenue$37.65K$131.52K$86.99K$0$0$0$939.93K
Cost of revenueUnavailableUnavailableUnavailable$0$0$0$369.60K
Gross profitUnavailableUnavailableUnavailable$0$0$0$570.33K
Operating income-$20.90M-$14.42M-$15.77M-$6.72M-$8.54M-$11.78M-$5.82M
Net income-$20.66M-$14.29M-$15.71M-$6.73M-$7.01M-$11.71M-$5.79M
Research & development$15.49M$10.07M$10.59M$3.54M$4.75M$8.73M$3.07M
Weighted-average diluted sharesshares 2.25Mshares 2.01MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$20.66M-$14.29M-$15.71M-$6.73M-$8.50M-$11.84M-$5.79M
Income tax expenseUnavailableUnavailableUnavailable$0$0$0$0
Diluted EPS$-9.18$-7.11UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable$3.54M$3.32M
General & administrative$5.45M$4.48M$5.27M$3.18M$3.79M$3.05MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ORAGENICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312017-12-312016-12-312015-12-312014-12-31
Cash & equivalents$3.48M$11.43M$27.27M$6.17M$4.08M$5.08M$10.45M
Total assets$4.97M$14.76M$28.23M$7.21M$4.31M$5.78M$11.13M
Current assets$3.87M$14.29M$27.71M$7.19M$4.22M$5.64M$11.02M
Total liabilities$1.80MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$1.80M$1.60M$1.45M$898.52K$1.34M$1.05M$796.27K
Total equity incl. NCI$3.17M$13.01M$26.49M$6.32M$2.97M$4.73M$10.34M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable$0$321.51K$439.19K
Accounts receivableUnavailableUnavailableUnavailableUnavailable$0$21.12K$15.61K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

ORAGENICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$7.29M-$15.23M-$13.47M-$6.36M-$7.08M-$5.19MUnavailable
Capital expendituresUnavailable$127.52K$43.88KUnavailable$27.18K$102.51K$110.67K
Investing cash flow-$936.28K-$115.52K-$43.88KUnavailable$1.68M-$101.23KUnavailable
Financing cash flow$283.88K-$494.92K$23.14M$8.45M$4.45M-$159.95KUnavailable
Net change in cash-$7.94M-$15.84M$9.63M$2.09M-$948.58K-$5.45M-$5.83M
Stock-based compensation$1.02M$742.20K$1.69MUnavailableUnavailable$770.70K$184.53K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$27.39K$44.67K$41.24K$65.80K$75.04K$71.15K$27.67K

Derived

ORAGENICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312022-12-312021-12-312017-12-312016-12-312015-12-312014-12-31
Free cash flowUnavailable-$15.36M-$13.51MUnavailable-$7.10M-$5.29MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable60.7%
Operating margin-55519.9%-10964.6%-18130.3%UnavailableUnavailableUnavailable-618.8%
FCF marginUnavailable-11675.7%-15535.8%UnavailableUnavailableUnavailableUnavailable
SBC / revenue2700.5%564.3%1940.5%UnavailableUnavailableUnavailable19.6%
Current ratioUnavailable8.95x19.17x8.01x3.14x5.38x13.84x
Revenue YoY growth-71.4%51.2%UnavailableUnavailableUnavailable-100.0%Unavailable
Net margin-54858.1%-10864.0%-18062.0%UnavailableUnavailableUnavailable-616.0%
R&D / revenue41140.4%7658.6%12169.8%UnavailableUnavailableUnavailable326.1%
CapEx / revenueUnavailable97.0%50.4%UnavailableUnavailableUnavailable11.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OGEN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.